Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Outcomes of localized prostate cancer following conservative management.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL.

JAMA. 2009 Sep 16;302(11):1202-9. doi: 10.1001/jama.2009.1348.

2.

Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships.

Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S.

J Clin Epidemiol. 2009 Dec;62(12):1226-32. doi: 10.1016/j.jclinepi.2008.12.005. Epub 2009 Apr 8.

3.

Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance.

Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S.

J Clin Epidemiol. 2009 Dec;62(12):1233-41. doi: 10.1016/j.jclinepi.2008.12.006. Epub 2009 Apr 5.

4.

Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans.

Riley GF, Warren JL, Potosky AL, Klabunde CN, Harlan LC, Osswald MB.

Med Care. 2008 Oct;46(10):1108-15. doi: 10.1097/MLR.0b013e3181862565.

PMID:
18815533
5.

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.

Bill-Axelson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; Scandinavian Prostate Cancer Group Study Number 4.

J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54. doi: 10.1093/jnci/djn255. Epub 2008 Aug 11.

6.

Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. Erratum in: JAMA. 2009 Jan 7;301(1):38.

7.

Limits of observational data in determining outcomes from cancer therapy.

Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS.

Cancer. 2008 Jun;112(11):2456-66. doi: 10.1002/cncr.23452.

8.

Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey.

Ross LE, Berkowitz Z, Ekwueme DU.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):636-44. doi: 10.1158/1055-9965.EPI-07-2709.

9.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
10.

Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling.

Terza JV, Basu A, Rathouz PJ.

J Health Econ. 2008 May;27(3):531-43. doi: 10.1016/j.jhealeco.2007.09.009. Epub 2007 Dec 4.

11.

Trends in prostate-specific antigen testing from 1995 through 2004.

Farwell WR, Linder JA, Jha AK.

Arch Intern Med. 2007 Dec 10;167(22):2497-502.

PMID:
18071173
12.
13.
14.

Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects?

Brookhart MA, Rassen JA, Wang PS, Dormuth C, Mogun H, Schneeweiss S.

Med Care. 2007 Oct;45(10 Supl 2):S116-22.

PMID:
17909369
15.

Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases.

Curtis LH, Hammill BG, Eisenstein EL, Kramer JM, Anstrom KJ.

Med Care. 2007 Oct;45(10 Supl 2):S103-7.

PMID:
17909367
16.

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer.

Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project.

Cancer. 2007 Oct 1;110(7):1493-500.

17.

A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D.

Ann Epidemiol. 2007 Aug;17(8):584-90. Epub 2007 May 25.

PMID:
17531502
18.
19.

13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.

Albertsen PC, Hanley JA, Penson DF, Barrows G, Fine J.

J Urol. 2007 Mar;177(3):932-6.

PMID:
17296379

Supplemental Content

Support Center